Blog
RSS FeedPosted by Michael Wonder on 18 Jun 2023
Health economic assessment of Carvykti in the treatment of multiple myeloma
16 June 2023 - TLV has prepared a health economic assessment for the regions for Carvykti (ciltacabtagene autoleucel). ...
Posted by Michael Wonder on 09 May 2022
Health economic assessment of Abecma in the treatment of multiple myeloma
6 May 2022 - TLV has produced a health economic assessment for the regions for Abecma (idecabtagene vicleucel). ...
Posted by Michael Wonder on 22 Feb 2022
Health economic assessment of the gene therapy Libmeldy in metachromatic leukodystrophy
22 February 2022 - Within the FINOSE collaboration, TLV, together with the corresponding authorities in Finland and Norway, has produced a ...
Posted by Michael Wonder on 20 Apr 2020
Additional analysis of Kymriah in the treatment of patients with diffuse large-cell B-cell lymphoma
17 April 2020 - TLV has conducted an additional analysis of the earlier evaluation of Kymriah (tisagenleclucel) in the treatment ...
Posted by Michael Wonder on 25 Jun 2019
Health economic assessment of Kymriah in diffuse large B-cell lymphoma
20 June 2019 - TLV has produced a health economic knowledge base for county councils for CAR-T cell treatment Kymriah ...